Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 19, 2019 - Issue 5
Submit an article Journal homepage
148
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial

Benjamin LacasDepartment of Biostatistic and Epidemiology, Gustave Roussy, Villejuif, FranceView further author information
,
Olivier BouchéDepartment of Digestive Oncology, Centre Hospitalier Universitaire, Reims, FranceView further author information
,
Pierre-Luc EtienneDepartment of Oncology, Clinique Armoricaine, Saint-Brieuc, FranceView further author information
,
Mohamed GasmiDepartment of Gastroenterology, Hôpital Nord, Marseille, FranceView further author information
,
Patrick TexereauDepartment of Oncology, Centre Hospitalier, Mont de Marsan, FranceView further author information
,
Dany GargotDepartment of Gastroenterology, Centre Hospitalier, Blois, FranceView further author information
,
Catherine Lombard-BohasDepartment of Medical Oncology, Centre Hospitalier Edouard Herriot, Lyon, FranceView further author information
,
Ahmed AzzedineDepartment of Gastroenterology, Centre Hospitalier, Avignon, FranceView further author information
,
Bernard DenisDepartment of Gastroenterology, Hôpital Louis Pasteur, Colmar, FranceView further author information
,
Patrick GeoffroyDepartment of Gastroenterology, Clinique St-Vincent, Epernay, FranceView further author information
,
Dominique AubyDepartment of Medical Oncology, Centre Hospitalier, Libourne, FranceView further author information
,
Pierre MichelDepartment of Gastroenterology, Hôpital Charles Nicolle, Rouen, FranceView further author information
,
Jean-Pierre PignonDepartment of Biostatistic and Epidemiology, Gustave Roussy, Villejuif, FranceView further author information
,
Côme LepageDepartment of Gastroenterology, Centre Hospitalier Universitaire, Dijon, FranceView further author information
,
Michel DucreuxDepartment of Medical Oncology, Gustave Roussy, Villejuif et Université Paris-Saclay, FranceView further author information
&
Isabelle BorgetDepartment of Biostatistic and Epidemiology, Gustave Roussy, Villejuif, FranceCorrespondence[email protected]
View further author information
 show all
Pages 601-608 | Received 03 Jul 2018, Accepted 06 Feb 2019, Published online: 15 Feb 2019

References

  • Incidence et mortalité estimées des principales localisations de cancers en France métropolitaine en. 2012. [cited 2019 Feb 19]. Available from: https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Synthese-Estimation-nationale-de-l-incidence-et-de-la-mortalite-par-cancer-en-France-entre-1980-et-2012-Partie-1-Tumeurs-solides
  • de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–2947.
  • Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041–1047.
  • Amalric F. Analyse économique des coûts du cancer en France. Boulogne-Billancourt: Institut national du cancer. 2007.
  • Goerner M, Riemer-Hommel P. Economic impact of alternative adjuvant chemotherapy regimens for stage III colon cancer. Onkologie. 2009;32:647–652.
  • Ajima H, Ogata H, Fujita K, et al. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer. Jpn J Clin Oncol. 2010;40:634–638.
  • Ducreux M, Malka D, Mendiboure J, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol. 2011;12:1032–1044. .
  • Choix méthodologiques pour l’évaluation économique à la HAS. [cited 2019 Feb 19]. Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-11/guide_methodo_vf.pdf
  • Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376.
  • Fayers P, Aaronson N, Bjordal K, et al. The EORTC QLQ-C30 scoring manual. 3rd. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
  • Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–144.
  • Tappenden P, Jones R, Paisley S, et al. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess. 2007;11:1–128.
  • Hoyle M, Crathorne L, Peters J, et al. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No. 150 and part review of technology appraisal No. 118): a systematic review and economic model. Health Technol Assess. 2013;17:1–237.
  • Graham CN, Hechmati G, Hjelmgren J, et al. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2014;50:2791–2801.
  • Parikh RC, Du XL, Robert MO, et al. Cost-effectiveness of treatment sequences of chemotherapies and targeted biologics for elderly metastatic colorectal cancer patients. J Manag Care Spec Pharm. 2017;23:64–73.
  • Tanenbaum SJ. What physicians know. N Engl J Med. 1993;329:1268–1271.
  • Naylor CD. Grey zones of clinical practice: some limits to evidence-based medicine. Lancet. 1995;345:840–842.
  • Rothwell PM. External validity of randomised controlled trials: “To whom do the results of this trial apply?”. Lancet. 2005;365:82–93.
  • Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342.
  • Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol. 2008;26:3523–3529.
  • Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–1544.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.